X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds of the Series B financing will be used to advance Noema Pharma's clinical-stage assets including its lead compound NOE-101 (basimglurant), an mGluR5 inhibitor which is being evaluated in Phase 2b clinical trials for severe pain in TN and seizures in TSC.
Lead Product(s): Basimglurant
Therapeutic Area: Neurology Product Name: NOE-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Forbion
Deal Size: $112.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 07, 2023
Details:
Basimglurant (NOE-101) is a highly selective, potent, and cell-penetrant negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5) for the treatment of trigeminal neuralgia (TN).
Lead Product(s): Basimglurant
Therapeutic Area: Neurology Product Name: NOE-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2022
Details:
NOE-101 (basimglurant), a highly selective, potent, and cell-penetrant negative allosteric modulator of mGlu5 receptors for the management of pain associated with TN.
Lead Product(s): Basimglurant
Therapeutic Area: Neurology Product Name: NOE-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
NOE-105 (gemlapodect) is an inhibitor of PDE10A, an enzyme highly expressed in medium spiny neurons of mammalian striatum, which modulates dopamine D2 receptor signaling and does not appear to be associated with metabolic abnormalities that are typically observed.
Lead Product(s): Gemlapodect
Therapeutic Area: Neurology Product Name: NOE-105
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2022
Details:
NOE-105 (gemlapodect) is an inhibitor of PDE10A, an enzyme highly expressed in medium spiny neurons of the mammalian striatum, which modulates D2 receptor signaling that are typically observed with most second-generation antipsychotics.
Lead Product(s): Gemlapodect
Therapeutic Area: Neurology Product Name: NOE-105
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2022
Details:
Financing will advance the development of four clinical-stage product candidates including lead product NOE-101. The product candidates will be developed in neurological indications with severe unmet need.
Lead Product(s): Basimglurant
Therapeutic Area: Neurology Product Name: NOE-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sofinnova Partners
Deal Size: $59.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing December 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
